# Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type

> **NCT00861120** · PHASE2 · COMPLETED · sponsor: **Vejle Hospital** · enrollment: 33 (estimated)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** Pegylated liposomal doxorubicin
- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT00861120
- **Lead sponsor:** Vejle Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2011-08
- **Final completion:** 2012-08
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2012-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00861120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00861120, "Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00861120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*